Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose
Francis Mwimanzi, Hope R. Lapointe, Peter K. Cheung, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 6, pp. 983-994
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Association of Frailty, Age, and Biological Sex With Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine–Induced Immunity in Older Adults
Janna R. Shapiro, Ioannis Sitaras, Han Sol Park, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. Supplement_1, pp. S61-S71
Open Access | Times Cited: 43
Immunosenescence and Altered Vaccine Efficiency in Older Subjects: A Myth Difficult to Change
Tamàs Fülöp, Anis Larbi, Graham Pawelec, et al.
Vaccines (2022) Vol. 10, Iss. 4, pp. 607-607
Open Access | Times Cited: 38
Challenges in the Vaccination of the Elderly and Strategies for Improvement
Gatot Soegiarto, Dewajani Purnomosari
Pathophysiology (2023) Vol. 30, Iss. 2, pp. 155-173
Open Access | Times Cited: 30
Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis
Zejun Li, Shouhuan Liu, Fengming Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 29
Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly
Isabella A. T. M. Ferreira, Colin Y. C. Lee, William S. Foster, et al.
Cell Reports (2023) Vol. 42, Iss. 8, pp. 112991-112991
Open Access | Times Cited: 16
SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series
Chapin S. Korosec, David W. Dick, Iain R. Moyles, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Covid-19 Vaccine (Nvx-Cov2373 and Nvx-Cov2540) Doses and Virus Strain Match Impact Sex- and Age-Specific Immunity and Protection in Mice
Sabal Chaulagain, Jaiprasath Sachithanandham, Jennifer Liu, et al.
(2025)
Closed Access
Durability of antibody titers and associated factors after the booster dose of COVID‐19 mRNA vaccination in Japanese SARS‐CoV‐2 infection‐naive residents in geriatric intermediate care facilities
Ayane Kasamatsu, Satoko Ohfuji, Asae Suita, et al.
Geriatrics and gerontology international/Geriatrics & gerontology international (2025)
Open Access
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study
Angioletta Lasagna, Federica Bergami, Daniele Lilleri, et al.
ESMO Open (2022) Vol. 7, Iss. 2, pp. 100458-100458
Open Access | Times Cited: 24
Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection
Fan Zhou, Juha Vahokoski, Siri Øyen, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 4
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy
Hope R. Lapointe, Francis Mwimanzi, Peter K. Cheung, et al.
AIDS (2022) Vol. 37, Iss. 5, pp. 709-721
Open Access | Times Cited: 18
SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy
Peter K. Cheung, Hope R. Lapointe, Yurou Sang, et al.
AIDS (2023) Vol. 37, Iss. 5, pp. F11-F18
Open Access | Times Cited: 11
Antibody and transcription landscape in peripheral blood mononuclear cells of elderly adults over 70 years of age with third dose of COVID-19 BBIBP-CorV and ZF2001 booster vaccine
Yuwei Zhang, Lianxiang Zhao, Jinzhong Zhang, et al.
Immunity & Ageing (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 3
Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June–July 2021)
O. V. Matveeva, А. В. Ершов
Vaccines (2022) Vol. 10, Iss. 7, pp. 984-984
Open Access | Times Cited: 16
Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2
Quentin Clairon, Mélanie Prague, Delphine Planas, et al.
PLoS Computational Biology (2023) Vol. 19, Iss. 8, pp. e1011282-e1011282
Open Access | Times Cited: 9
Elevated BMI reduces the humoral response to SARS‐CoV‐2 infection
Zhen Tong, Julian D. J. Sng, Meagan Carney, et al.
Clinical & Translational Immunology (2023) Vol. 12, Iss. 12
Open Access | Times Cited: 9
The effects of vaccination on the disease severity and factors for viral clearance and hospitalization in Omicron-infected patients: A retrospective observational cohort study from recent regional outbreaks in China
Hongru Li, Xiongpeng Zhu, Rongguo Yu, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 15
Subclinical SARS-CoV-2 Infections and Endemic Human Coronavirus Immunity Shape SARS-CoV-2 Saliva Antibody Responses
Tonia L. Conner, Emilie Goguet, Hannah Haines-Hull, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series
Sharon Walmsley, Leah Szadkowski, Bradly G. Wouters, et al.
iScience (2023) Vol. 26, Iss. 4, pp. 106506-106506
Open Access | Times Cited: 6
Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study
Alexandra G. Hillyer, Anthony Quint, Artin Ghassemian, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 5, pp. 305-315
Open Access | Times Cited: 1
Long-term levels of protection of different types of immunity against the Omicron variant: a rapid literature review
Sabina Rodriguez Velásquez, Loza Biru, Sandrine Marie Hakiza, et al.
Schweizerische medizinische Wochenschrift (2024) Vol. 154, Iss. 5, pp. 3732-3732
Open Access | Times Cited: 1
Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination
Hope R. Lapointe, Francis Mwimanzi, Peter K. Cheung, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8
Restoration of Neutralization Activity Against Omicron BA.2 and BA.5 in Older Adults and Individuals With Risk Factors Following the Fourth Dose of Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Vaccine
Masayuki Amano, Sachiko Otsu, Yasuko Ichikawa, et al.
The Journal of Infectious Diseases (2022) Vol. 227, Iss. 1, pp. 161-163
Open Access | Times Cited: 8
Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine
Francis Mwimanzi, Hope R. Lapointe, Peter K. Cheung, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 3
Open Access | Times Cited: 4
Dynamics of T-cell Responses Following COVID-19 mRNA Vaccination and Breakthrough Infection in Older Adults
Sneha Datwani, Rebecca Kalikawe, Francis Mwimanzi, et al.
Pathogens and Immunity (2023) Vol. 8, Iss. 1, pp. 117-135
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top